Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt’s lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib

Enhancer of zeste homolog 2 (EZH2) and Bruton’s tyrosine kinase (BTK) are both key factors involved in the development and progression of hematological malignancies. Clinical studies have demonstrated the potential of various EZH2 inhibitors, which target the methyltransferase activity of EZH2, for...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Yurim, Kim, Se Been, Yang, Chae-Eun, Yu, Min Seo, Choi, Wan-Su, Jeon, Youngwoo, Lim, Jung-Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518396/
https://www.ncbi.nlm.nih.gov/pubmed/37752998
http://dx.doi.org/10.3389/fonc.2023.1252658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518396/
https://www.ncbi.nlm.nih.gov/pubmed/37752998
http://dx.doi.org/10.3389/fonc.2023.1252658

Ejemplares similares